Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 294

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 294
---
.europa.eu/urostat/web/population -demography/population -housing-censuses/database — only population 18 and over was considered 2https://www.cdc.gov/diabetes/basics/prediabetes.html#:~:text=What%20Is%20Prediabetes%3F,t%20know%20they%20have%20it. 3https://diabetesatlas.org/data/en/region/3/eur.html 4https://www.mddionline.com/diabetes/look -competitive - landscape-diabetes -devices 5https://www.businesswire.com/news/home/20170519005456/en/According -to-THE-SAGE-GROUP-Peripheral-Artery-Disease- PAD -Afflicts-28-Million-Western-Europeans-and-4.2 -Million-Suffer-From-Critical-Limb-Ischemia-CLI— Numbers exclude UK which no longer honors CE mark 6https://www.businesswire.com/news/home/20170519005456/en/According -to-THE-SAGE-GROU P-Peripheral - Artery-Disease- PAD -Afflicts -28- Million-Western - Europeans-and -4.2 - Million-Suffer - From-Critical - Limb-Ischemia -CLI— Numbers exclude UK which no longer honors CE mark 7https://onlinelibrary.wiley.com/doi/abs/10.1002/hpm.2669 8Medtech 360 Report. Peripheral Vascular Devices Market Analysis US 2019 9Medtech 360 Report. Peripheral Vascular Devices Market Analysis US 2019

147 •Additional key assumptions regarding Lumee Oxygen include: •Revenue per subject in CLI would be equal to $600; •Product receives additional indication approval by the FDA for PAD in the US in 2027; •Product receives additional CE approval for PAD in Europe in 2028; •2030 average penetration rate of 1.86% across all indications and markets. Lumee Oxygen Revenue annual growth rates of: 2027 – 291%; 2028 – 127%; 2029 – 82%; 2030 – 60%.; •Regarding the Lumee Glucose product, Profusa’s assumptions include the size and growth of the market mentioned above, plus the inclusion of the type 2 market largely unserved by the CGM technology currently available. Profusa’s revenue assumptions are based on Profusa’s structural cost